Trial Profile
A phase III randomized open-label comparative study of standard whole brain radiation therapy with or without RSR13 [efaproxiral] in patients with brain metastases
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Efaproxiral (Primary)
- Indications Cancer metastases
- Focus Registrational; Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 15 Nov 2007 Status changed from in progress to completed.
- 28 Sep 2005 New trial record.